nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxepin—ORM1—Vemurafenib—melanoma	0.187	0.383	CbGbCtD
Doxepin—ABCB1—melanoma	0.116	1	CbGaD
Doxepin—CYP1A2—Carmustine—melanoma	0.0594	0.122	CbGbCtD
Doxepin—CYP1A2—Vemurafenib—melanoma	0.047	0.0964	CbGbCtD
Doxepin—CYP3A4—Temozolomide—melanoma	0.0449	0.0922	CbGbCtD
Doxepin—CYP2D6—Vemurafenib—melanoma	0.0387	0.0795	CbGbCtD
Doxepin—CYP1A2—Dacarbazine—melanoma	0.036	0.0739	CbGbCtD
Doxepin—ABCB1—Dactinomycin—melanoma	0.0273	0.056	CbGbCtD
Doxepin—CYP3A4—Vemurafenib—melanoma	0.0246	0.0505	CbGbCtD
Doxepin—ABCB1—Docetaxel—melanoma	0.0141	0.0289	CbGbCtD
Doxepin—CYP3A4—Docetaxel—melanoma	0.00845	0.0173	CbGbCtD
Doxepin—Olopatadine—S100B—melanoma	0.00222	0.581	CrCbGaD
Doxepin—CHRM5—skin epidermis—melanoma	0.00137	0.114	CbGeAlD
Doxepin—HTR2A—hindlimb—melanoma	0.000637	0.0532	CbGeAlD
Doxepin—HTR2A—appendage—melanoma	0.000546	0.0456	CbGeAlD
Doxepin—CHRM5—eye—melanoma	0.000488	0.0407	CbGeAlD
Doxepin—HRH2—skin of body—melanoma	0.000444	0.0371	CbGeAlD
Doxepin—CHRM5—skin of body—melanoma	0.000424	0.0354	CbGeAlD
Doxepin—Orphenadrine—SCN10A—melanoma	0.000395	0.103	CrCbGaD
Doxepin—Flushing—Temozolomide—melanoma	0.000383	0.00209	CcSEcCtD
Doxepin—Cardiac disorder—Temozolomide—melanoma	0.000383	0.00209	CcSEcCtD
Doxepin—Arrhythmia—Carmustine—melanoma	0.000381	0.00209	CcSEcCtD
Doxepin—Leukopenia—Bleomycin—melanoma	0.000381	0.00208	CcSEcCtD
Doxepin—Dizziness—Vemurafenib—melanoma	0.000379	0.00207	CcSEcCtD
Doxepin—Alopecia—Carmustine—melanoma	0.000377	0.00206	CcSEcCtD
Doxepin—Angiopathy—Temozolomide—melanoma	0.000374	0.00205	CcSEcCtD
Doxepin—Mental disorder—Carmustine—melanoma	0.000374	0.00205	CcSEcCtD
Doxepin—Ataxia—Docetaxel—melanoma	0.000373	0.00204	CcSEcCtD
Doxepin—Immune system disorder—Temozolomide—melanoma	0.000373	0.00204	CcSEcCtD
Doxepin—Mediastinal disorder—Temozolomide—melanoma	0.000372	0.00203	CcSEcCtD
Doxepin—Erythema—Carmustine—melanoma	0.000372	0.00203	CcSEcCtD
Doxepin—Malnutrition—Carmustine—melanoma	0.000372	0.00203	CcSEcCtD
Doxepin—Cough—Bleomycin—melanoma	0.000372	0.00203	CcSEcCtD
Doxepin—Chills—Temozolomide—melanoma	0.00037	0.00202	CcSEcCtD
Doxepin—Ill-defined disorder—Dactinomycin—melanoma	0.000368	0.00202	CcSEcCtD
Doxepin—Anaemia—Dactinomycin—melanoma	0.000367	0.00201	CcSEcCtD
Doxepin—Vomiting—Vemurafenib—melanoma	0.000365	0.00199	CcSEcCtD
Doxepin—Alopecia—Temozolomide—melanoma	0.000365	0.00199	CcSEcCtD
Doxepin—Chest pain—Bleomycin—melanoma	0.000363	0.00198	CcSEcCtD
Doxepin—Myalgia—Bleomycin—melanoma	0.000363	0.00198	CcSEcCtD
Doxepin—Rash—Vemurafenib—melanoma	0.000362	0.00198	CcSEcCtD
Doxepin—Mental disorder—Temozolomide—melanoma	0.000361	0.00198	CcSEcCtD
Doxepin—Dermatitis—Vemurafenib—melanoma	0.000361	0.00198	CcSEcCtD
Doxepin—Back pain—Carmustine—melanoma	0.00036	0.00197	CcSEcCtD
Doxepin—Headache—Vemurafenib—melanoma	0.000359	0.00197	CcSEcCtD
Doxepin—Erythema—Temozolomide—melanoma	0.000359	0.00196	CcSEcCtD
Doxepin—Malnutrition—Temozolomide—melanoma	0.000359	0.00196	CcSEcCtD
Doxepin—Breast disorder—Docetaxel—melanoma	0.000358	0.00196	CcSEcCtD
Doxepin—Discomfort—Bleomycin—melanoma	0.000358	0.00196	CcSEcCtD
Doxepin—Malaise—Dactinomycin—melanoma	0.000358	0.00196	CcSEcCtD
Doxepin—Cramp muscle—Docetaxel—melanoma	0.000357	0.00195	CcSEcCtD
Doxepin—Leukopenia—Dactinomycin—melanoma	0.000355	0.00194	CcSEcCtD
Doxepin—Nasopharyngitis—Docetaxel—melanoma	0.000355	0.00194	CcSEcCtD
Doxepin—CHRM4—head—melanoma	0.000354	0.0296	CbGeAlD
Doxepin—Dysgeusia—Temozolomide—melanoma	0.000352	0.00192	CcSEcCtD
Doxepin—Confusional state—Bleomycin—melanoma	0.00035	0.00192	CcSEcCtD
Doxepin—Vision blurred—Carmustine—melanoma	0.00035	0.00192	CcSEcCtD
Doxepin—Alanine aminotransferase increased—Docetaxel—melanoma	0.00035	0.00191	CcSEcCtD
Doxepin—Tremor—Carmustine—melanoma	0.000348	0.0019	CcSEcCtD
Doxepin—Oedema—Bleomycin—melanoma	0.000348	0.0019	CcSEcCtD
Doxepin—Back pain—Temozolomide—melanoma	0.000347	0.0019	CcSEcCtD
Doxepin—Infection—Bleomycin—melanoma	0.000345	0.00189	CcSEcCtD
Doxepin—Anaemia—Carmustine—melanoma	0.000344	0.00188	CcSEcCtD
Doxepin—Agitation—Carmustine—melanoma	0.000342	0.00187	CcSEcCtD
Doxepin—Nausea—Vemurafenib—melanoma	0.000341	0.00186	CcSEcCtD
Doxepin—Thrombocytopenia—Bleomycin—melanoma	0.00034	0.00186	CcSEcCtD
Doxepin—Vision blurred—Temozolomide—melanoma	0.000339	0.00185	CcSEcCtD
Doxepin—Myalgia—Dactinomycin—melanoma	0.000338	0.00185	CcSEcCtD
Doxepin—Tremor—Temozolomide—melanoma	0.000337	0.00184	CcSEcCtD
Doxepin—Discomfort—Dactinomycin—melanoma	0.000334	0.00183	CcSEcCtD
Doxepin—Ill-defined disorder—Temozolomide—melanoma	0.000333	0.00182	CcSEcCtD
Doxepin—Leukopenia—Carmustine—melanoma	0.000333	0.00182	CcSEcCtD
Doxepin—Anaemia—Temozolomide—melanoma	0.000332	0.00182	CcSEcCtD
Doxepin—Anorexia—Bleomycin—melanoma	0.000331	0.00181	CcSEcCtD
Doxepin—Agitation—Temozolomide—melanoma	0.00033	0.00181	CcSEcCtD
Doxepin—HTR2A—endothelium—melanoma	0.00033	0.0275	CbGeAlD
Doxepin—Pancytopenia—Docetaxel—melanoma	0.000326	0.00178	CcSEcCtD
Doxepin—Hypotension—Bleomycin—melanoma	0.000325	0.00178	CcSEcCtD
Doxepin—Oedema—Dactinomycin—melanoma	0.000324	0.00177	CcSEcCtD
Doxepin—Malaise—Temozolomide—melanoma	0.000324	0.00177	CcSEcCtD
Doxepin—Vertigo—Temozolomide—melanoma	0.000323	0.00176	CcSEcCtD
Doxepin—Convulsion—Carmustine—melanoma	0.000322	0.00176	CcSEcCtD
Doxepin—Infection—Dactinomycin—melanoma	0.000322	0.00176	CcSEcCtD
Doxepin—Leukopenia—Temozolomide—melanoma	0.000322	0.00176	CcSEcCtD
Doxepin—Hypertension—Carmustine—melanoma	0.000321	0.00176	CcSEcCtD
Doxepin—Palpitations—Temozolomide—melanoma	0.000317	0.00174	CcSEcCtD
Doxepin—Thrombocytopenia—Dactinomycin—melanoma	0.000317	0.00174	CcSEcCtD
Doxepin—HTR6—head—melanoma	0.000317	0.0265	CbGeAlD
Doxepin—Musculoskeletal discomfort—Bleomycin—melanoma	0.000317	0.00173	CcSEcCtD
Doxepin—Chest pain—Carmustine—melanoma	0.000316	0.00173	CcSEcCtD
Doxepin—Myalgia—Carmustine—melanoma	0.000316	0.00173	CcSEcCtD
Doxepin—Anxiety—Carmustine—melanoma	0.000315	0.00172	CcSEcCtD
Doxepin—Cough—Temozolomide—melanoma	0.000313	0.00171	CcSEcCtD
Doxepin—Paraesthesia—Bleomycin—melanoma	0.000312	0.00171	CcSEcCtD
Doxepin—Weight increased—Docetaxel—melanoma	0.000312	0.00171	CcSEcCtD
Doxepin—Convulsion—Temozolomide—melanoma	0.000311	0.0017	CcSEcCtD
Doxepin—Hypertension—Temozolomide—melanoma	0.00031	0.0017	CcSEcCtD
Doxepin—Dyspnoea—Bleomycin—melanoma	0.00031	0.00169	CcSEcCtD
Doxepin—Anorexia—Dactinomycin—melanoma	0.000309	0.00169	CcSEcCtD
Doxepin—Pneumonia—Docetaxel—melanoma	0.000307	0.00168	CcSEcCtD
Doxepin—Confusional state—Carmustine—melanoma	0.000306	0.00167	CcSEcCtD
Doxepin—Arthralgia—Temozolomide—melanoma	0.000306	0.00167	CcSEcCtD
Doxepin—Myalgia—Temozolomide—melanoma	0.000306	0.00167	CcSEcCtD
Doxepin—Infestation NOS—Docetaxel—melanoma	0.000306	0.00167	CcSEcCtD
Doxepin—Infestation—Docetaxel—melanoma	0.000306	0.00167	CcSEcCtD
Doxepin—Anxiety—Temozolomide—melanoma	0.000305	0.00167	CcSEcCtD
Doxepin—HTR2A—blood vessel—melanoma	0.000304	0.0254	CbGeAlD
Doxepin—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000304	0.00166	CcSEcCtD
Doxepin—Oedema—Carmustine—melanoma	0.000303	0.00166	CcSEcCtD
Doxepin—Discomfort—Temozolomide—melanoma	0.000302	0.00165	CcSEcCtD
Doxepin—Decreased appetite—Bleomycin—melanoma	0.000302	0.00165	CcSEcCtD
Doxepin—Infection—Carmustine—melanoma	0.000301	0.00165	CcSEcCtD
Doxepin—Neuropathy peripheral—Docetaxel—melanoma	0.0003	0.00164	CcSEcCtD
Doxepin—Dry mouth—Temozolomide—melanoma	0.000299	0.00164	CcSEcCtD
Doxepin—Stomatitis—Docetaxel—melanoma	0.000298	0.00163	CcSEcCtD
Doxepin—Jaundice—Docetaxel—melanoma	0.000298	0.00163	CcSEcCtD
Doxepin—Pain—Bleomycin—melanoma	0.000297	0.00163	CcSEcCtD
Doxepin—Thrombocytopenia—Carmustine—melanoma	0.000297	0.00162	CcSEcCtD
Doxepin—Tachycardia—Carmustine—melanoma	0.000296	0.00162	CcSEcCtD
Doxepin—Confusional state—Temozolomide—melanoma	0.000296	0.00162	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000295	0.00161	CcSEcCtD
Doxepin—Oedema—Temozolomide—melanoma	0.000293	0.0016	CcSEcCtD
Doxepin—Infection—Temozolomide—melanoma	0.000291	0.00159	CcSEcCtD
Doxepin—HRH2—head—melanoma	0.00029	0.0242	CbGeAlD
Doxepin—Anorexia—Carmustine—melanoma	0.000289	0.00158	CcSEcCtD
Doxepin—Hepatobiliary disease—Docetaxel—melanoma	0.000289	0.00158	CcSEcCtD
Doxepin—Nervous system disorder—Temozolomide—melanoma	0.000287	0.00157	CcSEcCtD
Doxepin—Thrombocytopenia—Temozolomide—melanoma	0.000287	0.00157	CcSEcCtD
Doxepin—Feeling abnormal—Bleomycin—melanoma	0.000286	0.00157	CcSEcCtD
Doxepin—Agranulocytosis—Docetaxel—melanoma	0.000285	0.00156	CcSEcCtD
Doxepin—Skin disorder—Temozolomide—melanoma	0.000285	0.00156	CcSEcCtD
Doxepin—Hypotension—Carmustine—melanoma	0.000283	0.00155	CcSEcCtD
Doxepin—Hyperhidrosis—Temozolomide—melanoma	0.000283	0.00155	CcSEcCtD
Doxepin—Decreased appetite—Dactinomycin—melanoma	0.000282	0.00154	CcSEcCtD
Doxepin—Fatigue—Dactinomycin—melanoma	0.000279	0.00153	CcSEcCtD
Doxepin—Anorexia—Temozolomide—melanoma	0.000279	0.00153	CcSEcCtD
Doxepin—Pain—Dactinomycin—melanoma	0.000277	0.00152	CcSEcCtD
Doxepin—CHRM5—head—melanoma	0.000277	0.0231	CbGeAlD
Doxepin—Musculoskeletal discomfort—Carmustine—melanoma	0.000276	0.00151	CcSEcCtD
Doxepin—Urticaria—Bleomycin—melanoma	0.000276	0.00151	CcSEcCtD
Doxepin—Body temperature increased—Bleomycin—melanoma	0.000275	0.0015	CcSEcCtD
Doxepin—Hepatitis—Docetaxel—melanoma	0.000274	0.0015	CcSEcCtD
Doxepin—Insomnia—Carmustine—melanoma	0.000274	0.0015	CcSEcCtD
Doxepin—Hypoaesthesia—Docetaxel—melanoma	0.000273	0.00149	CcSEcCtD
Doxepin—Paraesthesia—Carmustine—melanoma	0.000272	0.00149	CcSEcCtD
Doxepin—Pharyngitis—Docetaxel—melanoma	0.000272	0.00149	CcSEcCtD
Doxepin—Urinary tract disorder—Docetaxel—melanoma	0.000271	0.00148	CcSEcCtD
Doxepin—Dyspnoea—Carmustine—melanoma	0.00027	0.00148	CcSEcCtD
Doxepin—Oedema peripheral—Docetaxel—melanoma	0.00027	0.00148	CcSEcCtD
Doxepin—Somnolence—Carmustine—melanoma	0.00027	0.00147	CcSEcCtD
Doxepin—Connective tissue disorder—Docetaxel—melanoma	0.00027	0.00147	CcSEcCtD
Doxepin—Urethral disorder—Docetaxel—melanoma	0.000269	0.00147	CcSEcCtD
Doxepin—Feeling abnormal—Dactinomycin—melanoma	0.000267	0.00146	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Temozolomide—melanoma	0.000267	0.00146	CcSEcCtD
Doxepin—Insomnia—Temozolomide—melanoma	0.000265	0.00145	CcSEcCtD
Doxepin—Gastrointestinal pain—Dactinomycin—melanoma	0.000265	0.00145	CcSEcCtD
Doxepin—Decreased appetite—Carmustine—melanoma	0.000264	0.00144	CcSEcCtD
Doxepin—HTR2B—skin of body—melanoma	0.000264	0.022	CbGeAlD
Doxepin—Paraesthesia—Temozolomide—melanoma	0.000263	0.00144	CcSEcCtD
Doxepin—Gastrointestinal disorder—Carmustine—melanoma	0.000262	0.00143	CcSEcCtD
Doxepin—Dyspnoea—Temozolomide—melanoma	0.000261	0.00143	CcSEcCtD
Doxepin—Somnolence—Temozolomide—melanoma	0.000261	0.00143	CcSEcCtD
Doxepin—Constipation—Carmustine—melanoma	0.000259	0.00142	CcSEcCtD
Doxepin—Pain—Carmustine—melanoma	0.000259	0.00142	CcSEcCtD
Doxepin—Dyspepsia—Temozolomide—melanoma	0.000258	0.00141	CcSEcCtD
Doxepin—Eye disorder—Docetaxel—melanoma	0.000256	0.0014	CcSEcCtD
Doxepin—Abdominal pain—Dactinomycin—melanoma	0.000256	0.0014	CcSEcCtD
Doxepin—Body temperature increased—Dactinomycin—melanoma	0.000256	0.0014	CcSEcCtD
Doxepin—Hypersensitivity—Bleomycin—melanoma	0.000256	0.0014	CcSEcCtD
Doxepin—Decreased appetite—Temozolomide—melanoma	0.000255	0.00139	CcSEcCtD
Doxepin—Flushing—Docetaxel—melanoma	0.000255	0.00139	CcSEcCtD
Doxepin—Cardiac disorder—Docetaxel—melanoma	0.000255	0.00139	CcSEcCtD
Doxepin—Gastrointestinal disorder—Temozolomide—melanoma	0.000253	0.00138	CcSEcCtD
Doxepin—ADRA1B—head—melanoma	0.000253	0.0211	CbGeAlD
Doxepin—Fatigue—Temozolomide—melanoma	0.000253	0.00138	CcSEcCtD
Doxepin—Pain—Temozolomide—melanoma	0.000251	0.00137	CcSEcCtD
Doxepin—Constipation—Temozolomide—melanoma	0.000251	0.00137	CcSEcCtD
Doxepin—Feeling abnormal—Carmustine—melanoma	0.00025	0.00137	CcSEcCtD
Doxepin—Asthenia—Bleomycin—melanoma	0.000249	0.00136	CcSEcCtD
Doxepin—Angiopathy—Docetaxel—melanoma	0.000249	0.00136	CcSEcCtD
Doxepin—Gastrointestinal pain—Carmustine—melanoma	0.000248	0.00136	CcSEcCtD
Doxepin—Immune system disorder—Docetaxel—melanoma	0.000248	0.00136	CcSEcCtD
Doxepin—ADRA1D—head—melanoma	0.000247	0.0207	CbGeAlD
Doxepin—Mediastinal disorder—Docetaxel—melanoma	0.000247	0.00135	CcSEcCtD
Doxepin—Chills—Docetaxel—melanoma	0.000246	0.00135	CcSEcCtD
Doxepin—Pruritus—Bleomycin—melanoma	0.000246	0.00134	CcSEcCtD
Doxepin—DRD2—eye—melanoma	0.000245	0.0205	CbGeAlD
Doxepin—Arrhythmia—Docetaxel—melanoma	0.000245	0.00134	CcSEcCtD
Doxepin—DRD2—retina—melanoma	0.000243	0.0203	CbGeAlD
Doxepin—Alopecia—Docetaxel—melanoma	0.000242	0.00133	CcSEcCtD
Doxepin—Feeling abnormal—Temozolomide—melanoma	0.000242	0.00132	CcSEcCtD
Doxepin—Mental disorder—Docetaxel—melanoma	0.00024	0.00131	CcSEcCtD
Doxepin—Abdominal pain—Carmustine—melanoma	0.00024	0.00131	CcSEcCtD
Doxepin—Body temperature increased—Carmustine—melanoma	0.00024	0.00131	CcSEcCtD
Doxepin—Gastrointestinal pain—Temozolomide—melanoma	0.00024	0.00131	CcSEcCtD
Doxepin—Malnutrition—Docetaxel—melanoma	0.000239	0.00131	CcSEcCtD
Doxepin—Erythema—Docetaxel—melanoma	0.000239	0.00131	CcSEcCtD
Doxepin—Hypersensitivity—Dactinomycin—melanoma	0.000239	0.00131	CcSEcCtD
Doxepin—Dysgeusia—Docetaxel—melanoma	0.000234	0.00128	CcSEcCtD
Doxepin—Urticaria—Temozolomide—melanoma	0.000233	0.00127	CcSEcCtD
Doxepin—Asthenia—Dactinomycin—melanoma	0.000233	0.00127	CcSEcCtD
Doxepin—Abdominal pain—Temozolomide—melanoma	0.000232	0.00127	CcSEcCtD
Doxepin—Body temperature increased—Temozolomide—melanoma	0.000232	0.00127	CcSEcCtD
Doxepin—Back pain—Docetaxel—melanoma	0.000231	0.00126	CcSEcCtD
Doxepin—Muscle spasms—Docetaxel—melanoma	0.00023	0.00126	CcSEcCtD
Doxepin—Hypersensitivity—Carmustine—melanoma	0.000223	0.00122	CcSEcCtD
Doxepin—Diarrhoea—Dactinomycin—melanoma	0.000222	0.00121	CcSEcCtD
Doxepin—Vomiting—Bleomycin—melanoma	0.000221	0.00121	CcSEcCtD
Doxepin—Anaemia—Docetaxel—melanoma	0.000221	0.00121	CcSEcCtD
Doxepin—Rash—Bleomycin—melanoma	0.000219	0.0012	CcSEcCtD
Doxepin—Dermatitis—Bleomycin—melanoma	0.000219	0.0012	CcSEcCtD
Doxepin—Asthenia—Carmustine—melanoma	0.000218	0.00119	CcSEcCtD
Doxepin—HTR2A—neck—melanoma	0.000218	0.0182	CbGeAlD
Doxepin—Hypersensitivity—Temozolomide—melanoma	0.000216	0.00118	CcSEcCtD
Doxepin—Syncope—Docetaxel—melanoma	0.000214	0.00117	CcSEcCtD
Doxepin—Leukopenia—Docetaxel—melanoma	0.000214	0.00117	CcSEcCtD
Doxepin—Palpitations—Docetaxel—melanoma	0.000211	0.00115	CcSEcCtD
Doxepin—Asthenia—Temozolomide—melanoma	0.00021	0.00115	CcSEcCtD
Doxepin—Loss of consciousness—Docetaxel—melanoma	0.00021	0.00115	CcSEcCtD
Doxepin—Cough—Docetaxel—melanoma	0.000208	0.00114	CcSEcCtD
Doxepin—Diarrhoea—Carmustine—melanoma	0.000208	0.00114	CcSEcCtD
Doxepin—Pruritus—Temozolomide—melanoma	0.000207	0.00113	CcSEcCtD
Doxepin—Convulsion—Docetaxel—melanoma	0.000207	0.00113	CcSEcCtD
Doxepin—Nausea—Bleomycin—melanoma	0.000206	0.00113	CcSEcCtD
Doxepin—Hypertension—Docetaxel—melanoma	0.000206	0.00113	CcSEcCtD
Doxepin—Vomiting—Dactinomycin—melanoma	0.000206	0.00113	CcSEcCtD
Doxepin—Rash—Dactinomycin—melanoma	0.000204	0.00112	CcSEcCtD
Doxepin—Arthralgia—Docetaxel—melanoma	0.000203	0.00111	CcSEcCtD
Doxepin—Chest pain—Docetaxel—melanoma	0.000203	0.00111	CcSEcCtD
Doxepin—Myalgia—Docetaxel—melanoma	0.000203	0.00111	CcSEcCtD
Doxepin—HRH2—lymph node—melanoma	0.000203	0.0169	CbGeAlD
Doxepin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000202	0.0011	CcSEcCtD
Doxepin—Dizziness—Carmustine—melanoma	0.000201	0.0011	CcSEcCtD
Doxepin—Diarrhoea—Temozolomide—melanoma	0.000201	0.0011	CcSEcCtD
Doxepin—ABCB1—blood vessel—melanoma	0.000199	0.0166	CbGeAlD
Doxepin—Dry mouth—Docetaxel—melanoma	0.000199	0.00109	CcSEcCtD
Doxepin—Confusional state—Docetaxel—melanoma	0.000197	0.00108	CcSEcCtD
Doxepin—Oedema—Docetaxel—melanoma	0.000195	0.00107	CcSEcCtD
Doxepin—Dizziness—Temozolomide—melanoma	0.000194	0.00106	CcSEcCtD
Doxepin—HRH1—eye—melanoma	0.000194	0.0162	CbGeAlD
Doxepin—Infection—Docetaxel—melanoma	0.000194	0.00106	CcSEcCtD
Doxepin—Vomiting—Carmustine—melanoma	0.000193	0.00105	CcSEcCtD
Doxepin—Nausea—Dactinomycin—melanoma	0.000193	0.00105	CcSEcCtD
Doxepin—Shock—Docetaxel—melanoma	0.000192	0.00105	CcSEcCtD
Doxepin—Rash—Carmustine—melanoma	0.000191	0.00105	CcSEcCtD
Doxepin—Nervous system disorder—Docetaxel—melanoma	0.000191	0.00105	CcSEcCtD
Doxepin—Dermatitis—Carmustine—melanoma	0.000191	0.00105	CcSEcCtD
Doxepin—Thrombocytopenia—Docetaxel—melanoma	0.000191	0.00104	CcSEcCtD
Doxepin—Tachycardia—Docetaxel—melanoma	0.00019	0.00104	CcSEcCtD
Doxepin—Headache—Carmustine—melanoma	0.00019	0.00104	CcSEcCtD
Doxepin—CHRM2—head—melanoma	0.00019	0.0159	CbGeAlD
Doxepin—Skin disorder—Docetaxel—melanoma	0.000189	0.00104	CcSEcCtD
Doxepin—ADRA2C—mammalian vulva—melanoma	0.000189	0.0158	CbGeAlD
Doxepin—Vomiting—Temozolomide—melanoma	0.000186	0.00102	CcSEcCtD
Doxepin—Anorexia—Docetaxel—melanoma	0.000186	0.00102	CcSEcCtD
Doxepin—Oxcarbazepine—ALB—melanoma	0.000185	0.0484	CrCbGaD
Doxepin—Rash—Temozolomide—melanoma	0.000185	0.00101	CcSEcCtD
Doxepin—Dermatitis—Temozolomide—melanoma	0.000185	0.00101	CcSEcCtD
Doxepin—Headache—Temozolomide—melanoma	0.000184	0.001	CcSEcCtD
Doxepin—HTR2C—head—melanoma	0.000183	0.0153	CbGeAlD
Doxepin—Hypotension—Docetaxel—melanoma	0.000182	0.000996	CcSEcCtD
Doxepin—Nausea—Carmustine—melanoma	0.00018	0.000985	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Docetaxel—melanoma	0.000178	0.000971	CcSEcCtD
Doxepin—Insomnia—Docetaxel—melanoma	0.000176	0.000964	CcSEcCtD
Doxepin—Paraesthesia—Docetaxel—melanoma	0.000175	0.000957	CcSEcCtD
Doxepin—Nausea—Temozolomide—melanoma	0.000174	0.000952	CcSEcCtD
Doxepin—Dyspnoea—Docetaxel—melanoma	0.000174	0.000951	CcSEcCtD
Doxepin—SLC6A4—head—melanoma	0.000174	0.0145	CbGeAlD
Doxepin—Somnolence—Docetaxel—melanoma	0.000173	0.000948	CcSEcCtD
Doxepin—CHRM1—head—melanoma	0.000173	0.0144	CbGeAlD
Doxepin—HTR2B—head—melanoma	0.000172	0.0144	CbGeAlD
Doxepin—Dyspepsia—Docetaxel—melanoma	0.000172	0.000939	CcSEcCtD
Doxepin—Decreased appetite—Docetaxel—melanoma	0.000169	0.000927	CcSEcCtD
Doxepin—Gastrointestinal disorder—Docetaxel—melanoma	0.000168	0.00092	CcSEcCtD
Doxepin—Fatigue—Docetaxel—melanoma	0.000168	0.000919	CcSEcCtD
Doxepin—Pain—Docetaxel—melanoma	0.000167	0.000912	CcSEcCtD
Doxepin—Constipation—Docetaxel—melanoma	0.000167	0.000912	CcSEcCtD
Doxepin—HTR2A—eye—melanoma	0.000162	0.0135	CbGeAlD
Doxepin—Feeling abnormal—Docetaxel—melanoma	0.000161	0.000879	CcSEcCtD
Doxepin—HTR2A—retina—melanoma	0.00016	0.0134	CbGeAlD
Doxepin—Gastrointestinal pain—Docetaxel—melanoma	0.000159	0.000872	CcSEcCtD
Doxepin—CHRM3—head—melanoma	0.000155	0.0129	CbGeAlD
Doxepin—HTR1A—head—melanoma	0.000154	0.0129	CbGeAlD
Doxepin—Body temperature increased—Docetaxel—melanoma	0.000154	0.000843	CcSEcCtD
Doxepin—Abdominal pain—Docetaxel—melanoma	0.000154	0.000843	CcSEcCtD
Doxepin—HRH1—mammalian vulva—melanoma	0.000154	0.0128	CbGeAlD
Doxepin—SLC6A2—head—melanoma	0.000153	0.0128	CbGeAlD
Doxepin—ADRA2A—mammalian vulva—melanoma	0.000151	0.0126	CbGeAlD
Doxepin—Hypersensitivity—Docetaxel—melanoma	0.000144	0.000786	CcSEcCtD
Doxepin—ORM1—lymph node—melanoma	0.000143	0.0119	CbGeAlD
Doxepin—ADRA1A—head—melanoma	0.000142	0.0119	CbGeAlD
Doxepin—Asthenia—Docetaxel—melanoma	0.00014	0.000765	CcSEcCtD
Doxepin—DRD2—head—melanoma	0.000139	0.0116	CbGeAlD
Doxepin—Pruritus—Docetaxel—melanoma	0.000138	0.000754	CcSEcCtD
Doxepin—KCNH2—head—melanoma	0.000137	0.0115	CbGeAlD
Doxepin—ADRA2C—head—melanoma	0.000135	0.0113	CbGeAlD
Doxepin—Thiothixene—ALB—melanoma	0.000135	0.0352	CrCbGaD
Doxepin—Diarrhoea—Docetaxel—melanoma	0.000133	0.000729	CcSEcCtD
Doxepin—Dizziness—Docetaxel—melanoma	0.000129	0.000705	CcSEcCtD
Doxepin—Vomiting—Docetaxel—melanoma	0.000124	0.000678	CcSEcCtD
Doxepin—Rash—Docetaxel—melanoma	0.000123	0.000672	CcSEcCtD
Doxepin—Dermatitis—Docetaxel—melanoma	0.000123	0.000672	CcSEcCtD
Doxepin—Headache—Docetaxel—melanoma	0.000122	0.000668	CcSEcCtD
Doxepin—HTR2B—lymph node—melanoma	0.00012	0.0101	CbGeAlD
Doxepin—Nausea—Docetaxel—melanoma	0.000116	0.000633	CcSEcCtD
Doxepin—HRH1—head—melanoma	0.00011	0.00919	CbGeAlD
Doxepin—ADRA2A—head—melanoma	0.000108	0.00903	CbGeAlD
Doxepin—SLC6A2—lymph node—melanoma	0.000107	0.00894	CbGeAlD
Doxepin—Clomipramine—ALB—melanoma	0.000106	0.0278	CrCbGaD
Doxepin—ABCB1—retina—melanoma	0.000105	0.00878	CbGeAlD
Doxepin—Nortriptyline—ALB—melanoma	0.000104	0.0272	CrCbGaD
Doxepin—Clomipramine—ABCB1—melanoma	0.000102	0.0265	CrCbGaD
Doxepin—Chlorprothixene—ABCB1—melanoma	0.000101	0.0264	CrCbGaD
Doxepin—KCNH2—lymph node—melanoma	9.61e-05	0.00803	CbGeAlD
Doxepin—ADRA2C—lymph node—melanoma	9.48e-05	0.00792	CbGeAlD
Doxepin—Trimipramine—ABCB1—melanoma	9.34e-05	0.0244	CrCbGaD
Doxepin—HTR2A—head—melanoma	9.18e-05	0.00767	CbGeAlD
Doxepin—Promethazine—ABCB1—melanoma	8.99e-05	0.0235	CrCbGaD
Doxepin—ABCB1—mammalian vulva—melanoma	8.41e-05	0.00703	CbGeAlD
Doxepin—CYP2D6—head—melanoma	8.37e-05	0.00699	CbGeAlD
Doxepin—Desipramine—ABCB1—melanoma	8.17e-05	0.0213	CrCbGaD
Doxepin—HRH1—lymph node—melanoma	7.7e-05	0.00643	CbGeAlD
Doxepin—ADRA2A—lymph node—melanoma	7.56e-05	0.00632	CbGeAlD
Doxepin—Amitriptyline—ALB—melanoma	7.21e-05	0.0188	CrCbGaD
Doxepin—Imipramine—ABCB1—melanoma	6.93e-05	0.0181	CrCbGaD
Doxepin—Amitriptyline—ABCB1—melanoma	6.88e-05	0.018	CrCbGaD
Doxepin—ABCB1—head—melanoma	6.02e-05	0.00503	CbGeAlD
Doxepin—ABCB1—lymph node—melanoma	4.21e-05	0.00352	CbGeAlD
Doxepin—CHRM2—Signaling Pathways—MMP9—melanoma	3.08e-06	1.56e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—NFKB1—melanoma	3.08e-06	1.55e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—ALB—melanoma	3.07e-06	1.55e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—STAT3—melanoma	3.07e-06	1.55e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—MMP9—melanoma	3.07e-06	1.55e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—CDKN1A—melanoma	3.07e-06	1.55e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—MAPK3—melanoma	3.07e-06	1.55e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—NRAS—melanoma	3.07e-06	1.55e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—PTEN—melanoma	3.06e-06	1.55e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—CDKN1A—melanoma	3.06e-06	1.55e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—PTEN—melanoma	3.05e-06	1.54e-05	CbGpPWpGaD
Doxepin—ADRA2A—GPCR downstream signaling—AKT1—melanoma	3.05e-06	1.54e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—NFKB1—melanoma	3.05e-06	1.54e-05	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—IL6—melanoma	3.05e-06	1.54e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling by GPCR—AKT1—melanoma	3.04e-06	1.54e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—MAPK1—melanoma	3.04e-06	1.54e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—EGFR—melanoma	3.04e-06	1.53e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—NFKB1—melanoma	3.04e-06	1.53e-05	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—TP53—melanoma	3.04e-06	1.53e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling by GPCR—AKT1—melanoma	3.03e-06	1.53e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—ABCB1—melanoma	3.03e-06	1.53e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling by GPCR—AKT1—melanoma	3.02e-06	1.53e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—CASP3—melanoma	3.02e-06	1.52e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling by GPCR—AKT1—melanoma	3.02e-06	1.52e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—IL2—melanoma	3.01e-06	1.52e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—TP53—melanoma	3.01e-06	1.52e-05	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—HRAS—melanoma	3e-06	1.52e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling by GPCR—IL6—melanoma	3e-06	1.51e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—MYC—melanoma	3e-06	1.51e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling by GPCR—AKT1—melanoma	2.99e-06	1.51e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—MAPK3—melanoma	2.98e-06	1.51e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—MYC—melanoma	2.98e-06	1.51e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling by GPCR—AKT1—melanoma	2.98e-06	1.5e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.97e-06	1.5e-05	CbGpPWpGaD
Doxepin—ADRA2C—Metabolism—PIK3CA—melanoma	2.95e-06	1.49e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—CCND1—melanoma	2.94e-06	1.48e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—MAPK3—melanoma	2.94e-06	1.48e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—PIK3CD—melanoma	2.93e-06	1.48e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—MAPK1—melanoma	2.93e-06	1.48e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—EGFR—melanoma	2.93e-06	1.48e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—PIK3CA—melanoma	2.92e-06	1.48e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—MAPK1—melanoma	2.92e-06	1.47e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—EGFR—melanoma	2.92e-06	1.47e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—CTNNB1—melanoma	2.91e-06	1.47e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—PIK3CD—melanoma	2.91e-06	1.47e-05	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—HRAS—melanoma	2.9e-06	1.47e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—MYC—melanoma	2.9e-06	1.47e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—ALB—melanoma	2.9e-06	1.46e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—HRAS—melanoma	2.87e-06	1.45e-05	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—IL6—melanoma	2.87e-06	1.45e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—ALB—melanoma	2.87e-06	1.45e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—KRAS—melanoma	2.87e-06	1.45e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—VEGFA—melanoma	2.86e-06	1.45e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—MYC—melanoma	2.86e-06	1.44e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—MMP9—melanoma	2.85e-06	1.44e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—CDKN1A—melanoma	2.84e-06	1.44e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—MAPK1—melanoma	2.84e-06	1.43e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—EGFR—melanoma	2.84e-06	1.43e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—PTEN—melanoma	2.84e-06	1.43e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—STAT3—melanoma	2.83e-06	1.43e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PIK3CG—melanoma	2.83e-06	1.43e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—NRAS—melanoma	2.83e-06	1.43e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—TP53—melanoma	2.83e-06	1.43e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—NFKB1—melanoma	2.82e-06	1.43e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—VEGFA—melanoma	2.82e-06	1.42e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—VEGFA—melanoma	2.81e-06	1.42e-05	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—AKT1—melanoma	2.81e-06	1.42e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—VEGFA—melanoma	2.8e-06	1.41e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—MAPK1—melanoma	2.79e-06	1.41e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—EGFR—melanoma	2.79e-06	1.41e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—VEGFA—melanoma	2.79e-06	1.41e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—STAT3—melanoma	2.79e-06	1.41e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PRKCA—melanoma	2.79e-06	1.41e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—STAT3—melanoma	2.78e-06	1.41e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—NRAS—melanoma	2.78e-06	1.4e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—PIK3CB—melanoma	2.78e-06	1.4e-05	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—IL6—melanoma	2.78e-06	1.4e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—NRAS—melanoma	2.77e-06	1.4e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—STAT3—melanoma	2.77e-06	1.4e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—KRAS—melanoma	2.77e-06	1.4e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling by GPCR—AKT1—melanoma	2.77e-06	1.4e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—NRAS—melanoma	2.77e-06	1.4e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—VEGFA—melanoma	2.76e-06	1.4e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—STAT3—melanoma	2.76e-06	1.4e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—ERCC2—melanoma	2.76e-06	1.4e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—NRAS—melanoma	2.76e-06	1.39e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—VEGFA—melanoma	2.76e-06	1.39e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—KRAS—melanoma	2.76e-06	1.39e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—PTGS2—melanoma	2.76e-06	1.39e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—IL6—melanoma	2.75e-06	1.39e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—STAT3—melanoma	2.74e-06	1.38e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—NRAS—melanoma	2.73e-06	1.38e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—STAT3—melanoma	2.73e-06	1.38e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PPARG—melanoma	2.73e-06	1.38e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—NRAS—melanoma	2.72e-06	1.38e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—PIK3CB—melanoma	2.71e-06	1.37e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—MAPK3—melanoma	2.71e-06	1.37e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—HRAS—melanoma	2.7e-06	1.36e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—PTGS2—melanoma	2.69e-06	1.36e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—KRAS—melanoma	2.68e-06	1.35e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—MAPK3—melanoma	2.66e-06	1.35e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—MAPK3—melanoma	2.66e-06	1.34e-05	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—AKT1—melanoma	2.65e-06	1.34e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—MAPK3—melanoma	2.65e-06	1.34e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—MAPK3—melanoma	2.64e-06	1.33e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—KRAS—melanoma	2.64e-06	1.33e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—PIK3CA—melanoma	2.64e-06	1.33e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—MYC—melanoma	2.63e-06	1.33e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—MAPK3—melanoma	2.62e-06	1.32e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—MAPK3—melanoma	2.61e-06	1.32e-05	CbGpPWpGaD
Doxepin—CHRM3—Metabolism—PIK3CA—melanoma	2.61e-06	1.32e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—MYC—melanoma	2.59e-06	1.31e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—IL6—melanoma	2.59e-06	1.31e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—MYC—melanoma	2.58e-06	1.31e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—MYC—melanoma	2.58e-06	1.3e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—MAPK1—melanoma	2.58e-06	1.3e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—EGFR—melanoma	2.58e-06	1.3e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—MYC—melanoma	2.57e-06	1.3e-05	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—AKT1—melanoma	2.56e-06	1.3e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—VEGFA—melanoma	2.56e-06	1.29e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—PIK3CB—melanoma	2.56e-06	1.29e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—TP53—melanoma	2.55e-06	1.29e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—PIK3CA—melanoma	2.55e-06	1.29e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—MYC—melanoma	2.54e-06	1.28e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—AKT1—melanoma	2.54e-06	1.28e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—MYC—melanoma	2.54e-06	1.28e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—STAT3—melanoma	2.54e-06	1.28e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—PIK3CB—melanoma	2.54e-06	1.28e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—MAPK1—melanoma	2.53e-06	1.28e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—PTGS2—melanoma	2.53e-06	1.28e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—EGFR—melanoma	2.53e-06	1.28e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—PIK3CA—melanoma	2.53e-06	1.28e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—NRAS—melanoma	2.53e-06	1.28e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—MAPK1—melanoma	2.53e-06	1.28e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—EGFR—melanoma	2.53e-06	1.28e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—MAPK1—melanoma	2.52e-06	1.27e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—EGFR—melanoma	2.52e-06	1.27e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—MAPK1—melanoma	2.51e-06	1.27e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—PTGS2—melanoma	2.51e-06	1.27e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—EGFR—melanoma	2.51e-06	1.27e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—MAPK1—melanoma	2.49e-06	1.26e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—EGFR—melanoma	2.49e-06	1.26e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PIK3CD—melanoma	2.49e-06	1.26e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—MAPK1—melanoma	2.48e-06	1.25e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—EGFR—melanoma	2.48e-06	1.25e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—PIK3CA—melanoma	2.46e-06	1.24e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—TP53—melanoma	2.46e-06	1.24e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—ALB—melanoma	2.45e-06	1.24e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—TP53—melanoma	2.45e-06	1.24e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—HRAS—melanoma	2.44e-06	1.23e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—KRAS—melanoma	2.43e-06	1.23e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—PIK3CA—melanoma	2.42e-06	1.22e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—MAPK3—melanoma	2.42e-06	1.22e-05	CbGpPWpGaD
Doxepin—ADRA2C—Metabolism—AKT1—melanoma	2.41e-06	1.22e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—PTEN—melanoma	2.4e-06	1.21e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—KRAS—melanoma	2.39e-06	1.21e-05	CbGpPWpGaD
Doxepin—ADRA2A—Metabolism—PIK3CA—melanoma	2.39e-06	1.21e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—KRAS—melanoma	2.39e-06	1.21e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—AKT1—melanoma	2.39e-06	1.21e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—TP53—melanoma	2.38e-06	1.2e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—KRAS—melanoma	2.38e-06	1.2e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—KRAS—melanoma	2.37e-06	1.2e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—MYC—melanoma	2.36e-06	1.19e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—HRAS—melanoma	2.36e-06	1.19e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—KRAS—melanoma	2.35e-06	1.19e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—PTEN—melanoma	2.35e-06	1.18e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—TP53—melanoma	2.35e-06	1.18e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—KRAS—melanoma	2.34e-06	1.18e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—HRAS—melanoma	2.34e-06	1.18e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—IL6—melanoma	2.33e-06	1.18e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—MAPK1—melanoma	2.31e-06	1.16e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—EGFR—melanoma	2.31e-06	1.16e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—HRAS—melanoma	2.28e-06	1.15e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—IL6—melanoma	2.25e-06	1.14e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—HRAS—melanoma	2.24e-06	1.13e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—IL6—melanoma	2.24e-06	1.13e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—PIK3CA—melanoma	2.23e-06	1.13e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—PTEN—melanoma	2.21e-06	1.12e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—PIK3CA—melanoma	2.2e-06	1.11e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—PIK3CA—melanoma	2.19e-06	1.11e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—PTEN—melanoma	2.19e-06	1.11e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—PIK3CA—melanoma	2.19e-06	1.1e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PIK3CG—melanoma	2.18e-06	1.1e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—IL6—melanoma	2.18e-06	1.1e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—PIK3CA—melanoma	2.18e-06	1.1e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—KRAS—melanoma	2.18e-06	1.1e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PIK3CB—melanoma	2.17e-06	1.09e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—TP53—melanoma	2.16e-06	1.09e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—PIK3CA—melanoma	2.16e-06	1.09e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—AKT1—melanoma	2.15e-06	1.09e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—PIK3CA—melanoma	2.15e-06	1.09e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PTGS2—melanoma	2.15e-06	1.08e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—IL6—melanoma	2.15e-06	1.08e-05	CbGpPWpGaD
Doxepin—CHRM3—Metabolism—AKT1—melanoma	2.13e-06	1.08e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—TP53—melanoma	2.13e-06	1.07e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—TP53—melanoma	2.12e-06	1.07e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—TP53—melanoma	2.12e-06	1.07e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—TP53—melanoma	2.11e-06	1.07e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PPARG—melanoma	2.11e-06	1.06e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—TP53—melanoma	2.09e-06	1.06e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—TP53—melanoma	2.08e-06	1.05e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—AKT1—melanoma	2.08e-06	1.05e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—AKT1—melanoma	2.07e-06	1.05e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—HRAS—melanoma	2.07e-06	1.04e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—HRAS—melanoma	2.03e-06	1.03e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—HRAS—melanoma	2.03e-06	1.03e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—HRAS—melanoma	2.02e-06	1.02e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—HRAS—melanoma	2.02e-06	1.02e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—AKT1—melanoma	2.01e-06	1.02e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—PIK3CA—melanoma	2e-06	1.01e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—HRAS—melanoma	2e-06	1.01e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—HRAS—melanoma	1.99e-06	1.01e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—AKT1—melanoma	1.98e-06	1e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—IL6—melanoma	1.98e-06	1e-05	CbGpPWpGaD
Doxepin—ADRA2A—Metabolism—AKT1—melanoma	1.95e-06	9.87e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—IL6—melanoma	1.95e-06	9.84e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—IL6—melanoma	1.94e-06	9.82e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—IL6—melanoma	1.94e-06	9.78e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—TP53—melanoma	1.94e-06	9.78e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—IL6—melanoma	1.93e-06	9.75e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PIK3CD—melanoma	1.92e-06	9.69e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—IL6—melanoma	1.91e-06	9.66e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—IL6—melanoma	1.91e-06	9.63e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—ALB—melanoma	1.89e-06	9.57e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PTEN—melanoma	1.87e-06	9.46e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—HRAS—melanoma	1.85e-06	9.35e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—AKT1—melanoma	1.83e-06	9.22e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—AKT1—melanoma	1.8e-06	9.07e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—AKT1—melanoma	1.79e-06	9.06e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—AKT1—melanoma	1.79e-06	9.03e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—AKT1—melanoma	1.78e-06	9e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—IL6—melanoma	1.77e-06	8.95e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—AKT1—melanoma	1.76e-06	8.91e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—AKT1—melanoma	1.76e-06	8.89e-06	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—PIK3CA—melanoma	1.7e-06	8.56e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PIK3CB—melanoma	1.67e-06	8.45e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PTGS2—melanoma	1.66e-06	8.37e-06	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—PIK3CA—melanoma	1.65e-06	8.36e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—AKT1—melanoma	1.63e-06	8.26e-06	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—PIK3CA—melanoma	1.56e-06	7.88e-06	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—PIK3CA—melanoma	1.55e-06	7.81e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PTEN—melanoma	1.44e-06	7.3e-06	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—AKT1—melanoma	1.38e-06	7e-06	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—AKT1—melanoma	1.35e-06	6.83e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PIK3CA—melanoma	1.32e-06	6.67e-06	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—AKT1—melanoma	1.27e-06	6.43e-06	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—AKT1—melanoma	1.26e-06	6.38e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—AKT1—melanoma	1.08e-06	5.45e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PIK3CA—melanoma	1.02e-06	5.15e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—AKT1—melanoma	8.33e-07	4.21e-06	CbGpPWpGaD
